erlotinib hydrochloride has been researched along with ethacridine in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (ethacridine) | Trials (ethacridine) | Recent Studies (post-2010) (ethacridine) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 266 | 21 | 38 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | ethacridine (IC50) |
|---|---|---|---|
| Telomerase reverse transcriptase | Homo sapiens (human) | 8.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Awar, R; Aman, A; Datti, A; Gronda, M; Hurren, R; Lin, FH; MacLean, N; Minden, MD; Rotin, LE; Schimmer, AD; Wang, X; Wrana, JL | 1 |
1 other study(ies) available for erlotinib hydrochloride and ethacridine
| Article | Year |
|---|---|
Erlotinib synergizes with the poly(ADP-ribose) glycohydrolase inhibitor ethacridine in acute myeloid leukemia cells.
Topics: Cell Line, Tumor; Drug Synergism; Erlotinib Hydrochloride; Ethacridine; Glycoside Hydrolases; Humans; Leukemia, Myeloid, Acute | 2016 |